Brief: Abivax Provides 2024 Strategic Outlook, Lays Out Key Milestones Over Next 12 Months

Abivax SA

22/01/2024 07:35

Jan 22 (Reuters) - Abivax SA  ABVX.PA :
    * EQS-NEWS: ABIVAX PROVIDES 2024 STRATEGIC OUTLOOK AND LAYS
OUT
KEY MILESTONES OVER NEXT 12 MONTHS
    * INDUCTION DATA READ-OUT EXPECTED Q1 2025 FROM PIVOTAL
PHASE 3
ABTECT PROGRAM EVALUATING OBEFAZIMOD IN MODERATELY TO SEVERELY
ACTIVE ULCERATIVE COLITIS (UC)
    * FORMAL PROCESS EVALUATING ORAL AND INJECTABLE COMBINATION
THERAPY CANDIDATES WITH OBEFAZIMOD IN UC HAS COMMENCED;
PRECLINICAL DATA TO SUPPORT DECISION-MAKING ON COMBINATION AGENT
EXPECTED IN 2H 2024
    * TOP-LINE DATA FROM LONG-TERM EXTENSION TRIAL WITH 25MG
OBEFAZIMOD ONCE-DAILY ORAL AFTER ONE AND TWO YEARS OF TREATMENT
EXPECTED TO READ-OUT IN Q3 2024
    * IND FOR PHASE 2 TRIAL OF OBEFAZIMOD IN CROHN'S DISEASE
(CD)
CLEARED; ABIVAX TO CONSIDER PROTOCOL MODIFICATIONS BASED ON FDA
RECOMMENDATIONS
    * OBEFAZIMOD FOLLOW-ON CANDIDATE SELECTION EXPECTED IN Q3
2024
    * SEES IN Q4 2024: ABTECT PLANNED ENROLLMENT OF LAST PATIENT
INTO
INDUCTION TRIALS
    * SEES IN Q1 2025: ABTECT PLANNED TOP-LINE INDUCTION DATA
READ-OUT
AFTER EIGHT WEEKS OF TREATMENT
    * SEES IN Q1 2026: ABTECT PLANNED TOP-LINE MAINTENANCE
RESULTS
AFTER ONE YEAR OF TREATMENT

Source text for Eikon:  ID:nEQ112nR7a 
Further company coverage:  ABVX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))